Moderna to join Nasdaq 100, replacing Warner Bros Discovery
Moderna will be added to the Nasdaq 100 index on October 9, replacing Warner Bros Discovery. This change follows a significant increase in Moderna's stock price and market capitalization this year. Warner Bros Discovery's removal from major indexes like Nasdaq 100, MSCI, and S&P is linked to its impending combination with Paramount Skydance, scheduled for October 6.
Moderna, Inc. (MRNA) Options Chain
This article provides the options chain for Moderna, Inc. (MRNA), displaying delayed options data from NasdaqGS. It shows the stock's performance at market close and after hours, and indicates that there are currently no calls or puts listed for the given strike prices. The data is delayed by 15 minutes.
Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
This article compares two healthcare giants, Novo Nordisk and Pfizer, to determine which is a better investment in 2026. It analyzes their financials, risk profiles, and valuations, concluding that Pfizer, despite not being a high-growth stock, presents a better buy due to its current valuation and improving net income.
Merck & Co., Inc. (MRK) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Merck & Co., Inc. (MRK) stock, including its current price, recent news, and historical performance data. It highlights the stock's performance against the S&P 500, showing significant year-to-date and one-year returns, and lists various news articles related to Merck's drug trials and market performance. The page also includes details on trading activity, including overnight sessions.
PFIZER INC (PFE-USD.SW) interactive stock chart – Yahoo Finance
This Yahoo Finance page provides an interactive stock chart for PFIZER INC (PFE-USD.SW), displaying its current stock price and performance. It also aggregates recent news articles related to Pfizer, highlighting its drug developments, stock performance, and legal matters. The page serves as a hub for investors to quickly access financial data and news regarding Pfizer.
Nasdaq: Moderna, Inc. to Join the Nasdaq-100 Index Beginning Oct 9
Moderna, Inc. is set to join the Nasdaq-100 Index, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index, effective October 9. This inclusion signifies the company's growth and importance within the technology and innovation sectors. This move will likely impact investment strategies focusing on these indices.
Armata Pharmaceuticals Inc (ARMP-A) Stock Price and News
This article provides detailed stock information for Armata Pharmaceuticals Inc. (ARMP-A), including real-time quotes, price movements, and a comprehensive list of recent news and analyst reports. It also includes a company profile, highlighting Armata's focus on developing bacteriophage therapeutics for antibiotic-resistant infections.
Nasdaq Announces Moderna to Join Nasdaq-100 Index, Replacing Warner Bros. Discovery
Nasdaq announced that Moderna, Inc. will replace Warner Bros. Discovery, Inc. in the Nasdaq-100 Index, effective October 9, 2026, before market open. This change reflects Moderna's increasing market value and the index's focus on innovative companies, potentially boosting investor interest and trading volume for Moderna. The Nasdaq-100 Index tracks 100 of the largest non-financial companies listed on Nasdaq and is a significant benchmark globally.
United Therapeutics Jumps 13% After Court Backs Key Patent Claims Against Liquidia
United Therapeutics shares surged 13% after a Delaware federal judge ruled that Liquidia's Yutrepia infringed two valid patent claims related to inhaled treprostinil for PH-ILD, causing Liquidia's stock to drop over 50%. The court invalidated four other claims, and both companies have one week to propose remedies, with United Therapeutics seeking withdrawal of Yutrepia's approval and damages, while Liquidia plans to appeal. An analyst upgraded United Therapeutics to Buy with a $728 target following the decision.
Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
Nasdaq announced that Moderna, Inc. (MRNA) will be added to the Nasdaq-100 Index®, replacing Warner Bros. Discovery, Inc. (WBD), effective prior to market open on October 9, 2026. The Nasdaq-100 Index tracks 100 of the largest Nasdaq-listed non-financial companies and is a widely recognized benchmark for investment products. This change highlights Moderna's growing market presence and significance in the non-financial sector.
What’s Behind Iovance Biotherapeutics (IOVA) Latest Move?
Iovance Biotherapeutics (IOVA) recently raised its 2026 revenue outlook to US$410-420 million due to strong demand for Amtagvi and Proleukin, leading to a significant share price surge. While the stock has seen a 78.99% gain in 30 days and 243.85% in 90 days, its 5-year return is still down 44.45%, indicating a recent shift from poor performance to strong optimism. Despite ongoing net losses, the company is viewed by some as undervalued, with a fair value of $18 compared to its last close of $14.82, though others consider it expensive based on sales multiples.
Uthmeier alleges Pfizer misled Florida about its COVID vaccine’s safety
Florida Attorney General James Uthmeier has filed a lawsuit against Pfizer Inc., alleging unfair and deceptive marketing practices regarding its COVID-19 vaccine. The suit claims Pfizer misled Florida consumers about the vaccine's safety and efficacy while potentially concealing data on serious risks. Pfizer denies the allegations, stating its representations were accurate and science-based, and stands by the safety and efficacy of its vaccine.
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know
Vertex Pharmaceuticals Inc. (VRTX) saw its stock price drop by 3.21% due to macroeconomic headwinds like elevated treasury yields and investor scrutiny over its recent acquisition of Crinetics Pharmaceuticals. Technical indicators show a sell signal and an oversold condition, while fundamental analysis highlights risks such as cystic fibrosis market saturation, challenges in non-CF product launches, and rising operating expenses. Analysts have an average price target of $571.93, but revised earnings estimates suggest a cautious outlook.
Sellas Life Sciences Updates Executive Benefits Amid Retail Buyout Speculation
Sellas Life Sciences has revised executive benefits, extended its headquarters lease, and is nearing the final analysis of its Phase 3 Regal trial. These strategic moves, coupled with an improved retail investor sentiment, suggest the company is preparing for potential acquisition discussions and aiming to stabilize operations while awaiting crucial clinical results. Analysts maintain a "Buy" rating with price targets up to $35, citing promising developments in its cancer vaccine candidates.
Medpace Holdings Insider Sold Shares Worth $30,320,929, According to a Recent SEC Filing
An insider at Medpace Holdings has sold shares totaling $30,320,929, as reported in a recent SEC filing. This transaction is part of a series of insider share sales from the company, with previous sales ranging from hundreds of thousands to millions of dollars. Medpace Holdings is a global clinical contract research organization specializing in Phase I-IV clinical development services for the biotechnology, pharmaceutical, and medical device industries.
Moderna loses US government license defense in Northwestern patent case
A Delaware federal judge has rejected Moderna's argument that its sales of COVID-19 vaccines to the U.S. government should shield it from a patent infringement lawsuit filed by Northwestern University. The judge ruled that the Bayh-Dole Act, which governs federally funded research, does not provide a defense for non-government entities like Moderna. Northwestern's lawsuit, filed in 2024, alleges that Moderna misused its lipid nanoparticle technology in its vaccines, including Spikevax.
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Moderna's stock surged 3% despite a Citigroup downgrade to "Sell" with an $80 price target, indicating investor confidence in its cancer vaccine pipeline outweighs valuation concerns. BioNTech saw a smaller gain, while Pfizer's stock slipped, highlighting Moderna's isolated positive performance. The market is keenly awaiting Moderna's complete melanoma trial data in late October, which could determine the broader reach of its mRNA platform.
Citi Downgrades Moderna Stock, Warning $80 Billion Valuation Asks Too Much of Cancer Pipeline
Citi has downgraded Moderna stock from Hold to Sell, citing that its $80 billion valuation is not justified by its cancer pipeline fundamentals. Analyst Geoff Meacham raised the price target to $80 from $60 but believes the company's recent rally has outpaced its underlying value. This move suggests concerns about Moderna's ability to deliver on high expectations related to its pipeline projects.
Moderna, Inc. (MRNA) Adds COO; Andres Returns, Collins Retires
Moderna, Inc. (MRNA) has appointed Juan Andres as Chief Operating Officer, effective October 5, 2026, while Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer, will retire. This leadership change aims to strengthen operations ahead of potential oncology scaling and a broader vaccine portfolio. The company cited five approved vaccines, indicating increased complexity that the new COO role is expected to support.
Moderna Shares Reverse Weakness, Rise Over 3% After Key Trading Signal
Moderna (NASDAQ: MRNA) shares reversed an earlier decline, rising over 3% after a "Power Inflow" alert indicated significant institutional and retail buying interest. The alert, issued by TradePulse, signaled a strong shift towards buying activity, leading to a steady rise in the stock price from $186.46 to a post-alert high of $192.76. This event highlights the utility of order flow analytics in identifying potential bullish intraday momentum and short-term trading opportunities.
Morgan Stanley Names 3 Biotech Breakthroughs That Offer Investment Opportunities
Morgan Stanley has identified three significant biotech breakthroughs that present investment opportunities: Alzheimer's drugs, gene editing, and artificial intelligence (AI). The bank forecasts the Alzheimer's drug market at $70 billion and a $10 billion in-vivo gene editing market by 2035. For AI, Morgan Stanley favors companies supplying data, tools, and computing power, rather than drug developers, due to the unproven nature of AI raising drug success rates.
Serve Robotics (NASDAQ:SERV) Stock Sees Heavy Call Option Buying
Serve Robotics (NASDAQ:SERV) experienced heavy call option buying, with traders purchasing 18,450 call options, a 15% increase over the average daily volume. This occurred despite recent insider stock sales to cover tax obligations, a larger-than-expected quarterly loss, and weaker-than-expected revenue, which have driven the stock near its one-year low. Analyst sentiment remains a "Moderate Buy" with an average price target of $14.77, though several firms recently cut targets to $7.00.
Lexicon Pharmaceuticals upgraded to Buy with key drug trial results and NDA plans ahead.
Lexicon Pharmaceuticals has received a "Buy" rating due to upcoming catalysts, including the planned resubmission of its New Drug Application for ZYNQUISTA in Type 1 Diabetes by Q4 2026 and anticipated Phase 3 trial results for sotagliflozin in Q1 2027. Additionally, a potential partnership with Novo Nordisk for LX9851 could yield significant milestone payments. These developments suggest a promising investment outlook for the biotech company.
Cramer's lightning round: Buy Kinder Morgan
Jim Cramer conducted his "lightning round," offering rapid-fire stock advice to callers. He recommended buying Kinder Morgan, deeming it undervalued, and suggested Grail stock could go higher. Cramer also advised against stocks losing money, like POET Technologies, and commented on MPLX LP's strong dividend and StandardAero's potential for a downward move before a buying opportunity.
What's Going On With Moderna Stock on Wednesday?
Moderna's stock dropped on Wednesday following an executive leadership update, including the addition of a Chief Operating Officer and the retirement of the Chief Technical Operations and Quality Officer. The company is preparing for the potential launch of intismeran autogene for oncology and has expanded its infectious disease vaccine franchise with recent FDA and European approvals. This comes after positive Phase 3 results for its individualized cancer therapy, and the recent approval of updated COVID-19 vaccine formulas.
SoundHound AI Jumps 5% on India Product Launch; BigBear.ai Rises 3%, Pony AI Stays Flat
SoundHound AI's stock surged 5% after launching generative voice AI in the Kia Sorento in India, a market first that also coincided with strong Q2 revenue. BigBear.ai saw a 3% gain due to broad interest in applied-AI platforms, while Pony AI remained flat. The article highlights SoundHound AI's expansion in automotive markets and its OASYS Edge architecture, which is set for late 2026 deployment, allowing for local voice AI operation without cloud dependency.
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
Moderna (MRNA) and BioNTech (BNTX), both prominent in mRNA technology, are transitioning from COVID-19 vaccine reliance to developing new therapies. Moderna appears to be further along in this diversification, with approved respiratory vaccines and positive late-stage oncology results. BioNTech, while having a broader oncology pipeline, faces greater challenges with revenue replacement as COVID-19 vaccine demand normalizes and has experienced recent clinical setbacks.
This Pharma Giant Has The Right Medicine For Income Investors
Bristol Myers Squibb (BMY) is presented as a strong option for income investors seeking high yield and stable fundamentals in the healthcare sector. The pharmaceutical giant, based in Princeton, N.J., develops medicines for serious diseases and boasts a deep pipeline of 49 compounds. This extensive portfolio distinguishes it from smaller drugmakers that are often dependent on the success of only one or two products.
This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
This article highlights the top five analyst downgrades for Wednesday, September 30, 2026. Analysts from Roth Capital, Citigroup, TD Cowen, and Barclays revised their ratings and price targets for companies including SoundThinking Inc, Moderna Inc, Accelerant Holdings, Mobileye Global Inc, and Dow Inc. The downgrades reflect a change in outlook from bullish to neutral or sell for these stocks.
MRNA Stock Downgraded As Valuation Fears Eclipse Cancer Win
Moderna Inc. (MRNA) stock was downgraded to "Sell" by Rothschild & Co Redburn, despite a successful Phase 3 cancer vaccine trial, due to concerns that its valuation already incorporates unrealistic expectations. The downgrade led to a 7.29% drop in MRNA's stock, highlighting a divergence between strong clinical results and an aggressive valuation, as the broader analyst consensus remains "Hold." Traders are now navigating increased volatility as the market weighs the long-term potential of the cancer vaccine against immediate valuation risks.
Premarket movers: Micron; Boeing rises, Moderna slides
U.S. stock index futures were largely flat on Wednesday as investors awaited key inflation data and Micron's earnings. Boeing surged after securing a major contract for the Navy's F/A-XX fighter, while Moderna slid following a downgrade from Citi. Concentrix plunged after disappointing revenue guidance, and Trulieve Cannabis also fell despite a new licensing agreement.
Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s
Concentrix Corporation reported mixed third-quarter financial results, with earnings beating estimates but sales missing, leading to a 10.6% drop in pre-market trading. The company also issued weak guidance for the current quarter and lowered its FY26 sales outlook. Several other stocks, including Cal-Maine Foods, Trulieve Cannabis, and Moderna, also saw declines in pre-market trading on Wednesday.
MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum
Moderna (MRNA) shares fell in premarket trading after Citi downgraded the stock from Neutral to Sell, citing stretched valuation despite recent positive cancer vaccine trial results. Citi analyst Geoff Meacham noted Moderna's market capitalization is now similar to Regeneron but with significantly lower expected revenue and earnings. The downgrade follows a 222% surge in MRNA shares since the positive INTerpath-001 trial results for its individualized mRNA-based neoantigen therapy in melanoma.
Cigna Group reaffirms 2026 outlook at investor day
The Cigna Group reaffirmed its full-year 2026 financial outlook during its Investor Day, projecting consolidated adjusted revenues of approximately $280 billion and adjusted earnings per share of at least $30.45. The company also set segment-level targets for Evernorth Health Services and Cigna Healthcare, alongside a long-term average annual adjusted EPS growth target of 10% to 14%. These figures were previously discussed in a July 2026 press release.
Moderna has been on a tear since mid-August. Citi now sees it plunging 60%
Citi analyst Geoff Meacham has downgraded Moderna stock to "sell" despite its recent rally, citing unsustainable valuation levels. Moderna shares have surged 223% since August 19 after positive trial results for a cancer vaccine. However, Meacham believes the current market capitalization and implied sales for its oncology programs are unjustifiably high, indicating a potential 60% downside.
Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Moderna has announced the creation of a Chief Operating Officer role to support its expanding operations and diversification into oncology and expanded infectious disease franchises. Juan Andres will return to Moderna as COO, effective October 5, 2026, reporting to CEO Stéphane Bancel. Jerh Collins, the current Chief Technical Operations and Quality Officer, will retire, with both Bancel and Collins expressing gratitude for his contributions.
Goldman Sachs Adjusts PT on DuPont de Nemours to $153 From $159, Keeps Neutral Rating
Goldman Sachs has adjusted its price target for DuPont de Nemours (NYSE: DD) to $153 from $159, while maintaining a Neutral rating on the stock. This update reflects the firm's latest analysis of the specialty chemicals company. DuPont de Nemours continues to be a subject of analyst evaluations, with other firms also providing updated price targets recently.
Is Arista Networks Stock As Expensive As It Looks?
Arista Networks (ANET) stock appears expensive with a trailing P/E of 58.3x, but its valuation improves to 49.2x for fiscal 2026 and 38.9x for fiscal 2027 based on analyst forecasts. The company has shown strong sales growth (33% over the last twelve months) and management has raised its fiscal 2026 sales outlook. However, risks such as industry-wide supply tightness and rising component costs could impact future earnings, making the stock a riskier bet if forecasts are not met.
Moderna Sets Another Fresh 52-Week High: What's Happening?
Moderna (NASDAQ: MRNA) shares have reached a new 52-week high of $208.90, driven by strong clinical trial news, particularly for its experimental cancer drug, intismeran autogene. The stock's technical setup remains bullish despite momentum readings indicating overbought levels. Moderna is outperforming its healthcare sector, which is currently struggling.
Bayer Advances Patent Suit Over Moderna, Pfizer Covid Vaccines
A federal judge in Delaware has denied attempts by Moderna and Pfizer to dismiss lawsuits filed by Bayer. Bayer accuses the vaccine makers of infringing on a crop-based genetic-engineering patent (US Patent No. 7,741,118) with their Covid-19 vaccines. The judge rejected arguments that Bayer's patent was ineligible for attempting to monopolize a natural phenomenon or being abstract.
Precision Trading with Moderna Inc. (MRNA) Risk Zones
This article analyzes Moderna Inc. (MRNA) using AI models to provide trading strategies and risk zones. It highlights strong sentiment across all horizons supporting an overweight bias and identifies compelling upside potential due to the absence of resistance levels above the current price. Three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are presented, tailored for different risk profiles.
Moderna stock hits 52-week high at 202.69 USD
Moderna's stock has reached a new 52-week high of $202.69, currently trading at $203.24 with a market capitalization of $79.65 billion, reflecting an impressive 678.84% return over the past year. Despite its overvalued status according to InvestingPro, investor confidence is high due to its role in COVID-19 vaccines and continued innovation. The company faces ongoing patent lawsuits, while analysts hold mixed views on its future performance, with ratings ranging from Sell to Buy.
These ten healthcare stocks posted the biggest September gains
This article identifies the top 10 performing healthcare stocks for September 2026, highlighting significant gains in various sub-sectors like Biotechnology and Health Care Technology. Kodiak Sciences Inc. led with a 138.39% increase, followed by GRAIL, Inc. and Schrödinger, Inc. The list also notes several stocks with "Strong Buy" Quant Ratings from Seeking Alpha.
Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency
Prime Medicine (Nasdaq: PRME) has received FDA clearance for PM647, a one-time in vivo prime editing therapy for alpha-1 antitrypsin deficiency (AATD). This therapy aims to correct the genetic defect, addressing both lung and liver manifestations with a single treatment. Initial clinical data are anticipated in 2027, placing PM647 in a competitive field of genetic medicines for AATD.
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The State Street SPDR S&P Biotech ETF (XBI) offers broad exposure to the Health Care ETFs category, utilizing a smart beta, modified equal-weighting methodology. With over $10.66 billion in assets and a low expense ratio of 0.35%, XBI has shown strong year-to-date and 12-month performance, though it's considered a high-risk option. The ETF primarily invests in the Healthcare sector, with top holdings including Moderna Inc, Twist Bioscience Corp, and Halozyme Therapeutics Inc.
Form 8-K NEWS CORP For: Sep 25
This article reports on NEWS CORP's Form 8-K filing dated September 25, 2026. The filing details the company's stock repurchase program, under which it is authorized to acquire up to $1 billion of its Class A and Class B common stock. It also states the company's obligation to provide daily disclosures to the ASX regarding these transactions and includes forward-looking statements about the repurchase program.
Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits (PFE:NYSE)
A Delaware federal judge has rejected requests from Pfizer, BioNTech, and Moderna to dismiss patent lawsuits filed by Bayer's Monsanto unit. The lawsuits concern the drugmakers' use of a patent related to mRNA technology. This decision means the lawsuits can proceed against the pharmaceutical companies.
Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuit
A federal judge in Delaware rejected requests from Pfizer, BioNTech, and Moderna to dismiss patent lawsuits filed by Bayer's Monsanto unit. Bayer alleges that the COVID-19 vaccine makers copied its messenger RNA technology, originally developed for crops, to stabilize the genetic material in their vaccines. The vaccine makers argued their processes differed and Moderna claimed the patent covered an unpatentable "law of nature."
Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?
This article compares Moderna (MRNA) and BioNTech Se (BNTX) as mRNA cancer stocks, discussing their respective strengths. Moderna has recently delivered pivotal cancer results, while BioNTech offers greater financial flexibility and a broader oncology pipeline. The piece questions whether Moderna's valuation premium is justified by its clinical proof or if BioNTech's multiple pathways to success present a more attractive long-term investment.
Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?
Moderna's stock has surged over 550% this year following positive Phase 3 trial results for its cancer vaccine, intismeran, developed with Merck. While this development is promising, analysts suggest the stock's current valuation might be too optimistic, with a consensus price target significantly lower than its recent trading price. The article advises caution, suggesting that despite potential billions in revenue, it might not justify the current high valuation.
